Literature DB >> 21388295

Synergistic effects of arsenic trioxide and radiation in osteosarcoma cells through the induction of both autophagy and apoptosis.

Hui-Wen Chiu1, Wei Lin, Sheng-Yow Ho, Ying-Jan Wang.   

Abstract

Osteosarcoma is the most common primary malignant bone tumor, occurring mainly in children and adolescents, and survival largely depends on their response to chemotherapy. However, the risk of relapse and adverse outcomes is still high. We investigated the synergistic anti-cancer effects of ionizing radiation combined with arsenic trioxide (ATO) and the mechanisms underlying apoptosis or autophagy induced by combined radiation and ATO treatment in human osteosarcoma cells. We found that exposure to radiation increased the population of HOS cells in the G(2)/M phase within 12 h in a time-dependent manner. Radiation combined with ATO induced a significantly prolonged G(2)/M arrest, consequently enhancing cell death. Furthermore, combined treatment resulted in enhanced ROS generation compared to treatment with ATO or radiation alone. The enhanced cytotoxic effect of combined treatment occurred from the increased induction of autophagy and apoptosis through inhibition of the PI3K/Akt signaling pathway in HOS cells. The combined treatment of HOS cells pretreated with Z-VAD, 3-MA or PEG-catalase resulted in a significant reduction of cytotoxicity. In addition, G(2)/M arrest and ROS generation could be involved in the underlying mechanisms. The data suggest that a combination of radiation and ATO could be a new potential therapeutic strategy for the treatment of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21388295     DOI: 10.1667/RR2380.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  8 in total

Review 1.  Progress in radiotherapy for pediatric sarcomas.

Authors:  Susan L McGovern; Anita Mahajan
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

Review 2.  Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury.

Authors:  Edouard I Azzam; Jean-Paul Jay-Gerin; Debkumar Pain
Journal:  Cancer Lett       Date:  2011-12-17       Impact factor: 8.679

Review 3.  Autophagy in tumor suppression and cancer therapy.

Authors:  Che-Pei Kung; Anna Budina; Gregor Balaburski; Marika K Bergenstock; Maureen Murphy
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

4.  Autophagy inhibition enhances apigenin-induced apoptosis in human breast cancer cells.

Authors:  Xuchen Cao; Bowen Liu; Wenfeng Cao; Weiran Zhang; Fei Zhang; Hongmeng Zhao; Ran Meng; Lin Zhang; Ruifang Niu; Xishan Hao; Bin Zhang
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

Review 5.  Autophagy in Osteosarcoma.

Authors:  Grace Nehme; Nancy Gordon
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 3.650

Review 6.  Hedgehog signaling inhibitors as anti-cancer agents in osteosarcoma.

Authors:  Ram Mohan Ram Kumar; Bruno Fuchs
Journal:  Cancers (Basel)       Date:  2015-05-13       Impact factor: 6.639

7.  Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy.

Authors:  Claudia Paret; Alexandra Russo; Henrike Otto; Arnulf Mayer; Sebastian Zahnreich; Wolfgang Wagner; David Samuel; David Scharnhorst; David A Solomon; Girish Dhall; Kenneth Wong; Hannah Bender; Francesca Alt; Arthur Wingerter; Marie A Neu; Olaf Beck; Dirk Prawitt; Stefan Eder; Nicole Henninger; Khalifa El Malki; Nadine Lehmann; Nora Backes; Lea Roth; Larissa Seidmann; Clemens Sommer; Marc A Brockmann; Gundula Staatz; Heinz Schmidberger; Jörg Faber
Journal:  Oncotarget       Date:  2017-12-11

8.  Autophagy-inducing effect of pterostilbene: A prospective therapeutic/preventive option for skin diseases.

Authors:  Rong-Jane Chen; Yu-Hsuan Lee; Ya-Ling Yeh; Wun-Syuan Wu; Chi-Tang Ho; Chia-Yi Li; Bour-Jr Wang; Ying-Jan Wang
Journal:  J Food Drug Anal       Date:  2016-12-11       Impact factor: 6.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.